Tel Aviv — November 19, 2025 — Teva Pharmaceutical Industries Ltd. has launched Teva Rise, a groundbreaking global open-innovation platform designed to accelerate AI-driven drug development, Industry 4.0 smart manufacturing, digital health innovation, and biotech breakthroughs by connecting startups and technology companies with Teva’s worldwide operations. Positioned as a core pillar of Teva’s Pivot to Growth strategy, the platform aims to deliver scalable, real-world solutions to some of the most pressing challenges across the pharmaceutical value chain.
Science Significance
Teva Rise represents a major scientific advancement by enabling external innovators to address seven high-impact challenges across R&D, clinical development, manufacturing, and supply-chain science. These include human-predictive biologics testing platforms—such as organ-on-chip and advanced cell-culture models—to enhance preclinical decision-making; AI-powered clinical-trial protocol simulation to optimize enrollment, reduce amendments, and strengthen study design; and AI/ML-based product-quality prediction to identify risks earlier in development. The program’s scientific architecture underscores a shift toward data-driven, model-informed drug development, accelerating timelines and improving experimental robustness.
Advertisement
Regulatory Significance
From a regulatory perspective, the platform directly supports next-generation GxP-aligned innovation, enabling startups to co-develop tools that enhance regulatory compliance and quality-system performance. Challenges such as predictive maintenance, risk-based quality modeling, and clinical-trial simulation using machine learning align with increasing regulatory expectations for digital validation, data integrity, model-informed evidence, and advanced statistical approaches. By fostering technologies that improve transparency, reliability, and audit readiness across the value chain, Teva Rise positions the company to advance more robust CMC packages, strengthen clinical operations, and improve alignment with global regulatory agencies.
Business Significance
The business significance of Teva Rise is substantial, as the platform operationalizes Teva’s corporate commitment to innovation while accelerating business transformation across global markets. By issuing a call-to-innovate for seven major challenge areas—ranging from analytics-driven tender optimization to AI-based resource-allocation intelligence—Teva is opening its operational ecosystem to technology partners worldwide. Startups selected for the program will have the opportunity to pilot, integrate, and scale their solutions across Teva’s facilities in the U.S., Europe, Israel, and beyond. The company anticipates investing tens of millions of dollars over the coming years to adopt technologies that deliver competitive advantage, operational efficiency, and long-term growth. As Teva continues its evolution into a leading biopharmaceutical company, the Rise platform strengthens its ability to remain agile, technologically advanced, and commercially resilient.
Patients’ Significance
For patients, Teva Rise represents a future in which integrated digital health tools, smarter manufacturing, and improved therapeutic development pathways translate into more reliable, effective, and accessible treatments. Challenges focused on long-acting injectable patient-experience improvements and intelligent monitoring technologies have the potential to enhance adherence, reduce healthcare burden, and improve quality of life. Meanwhile, innovations that improve manufacturing reliability and supply-chain resilience help reduce shortages and ensure patients receive safe, high-quality medicines consistently. By connecting global innovators with real-world needs, Teva Rise creates an ecosystem that accelerates technologies that could materially shape patient outcomes across therapeutic areas.
Policy Significance
Teva Rise aligns with emerging health-policy priorities around digital transformation, open innovation, AI adoption, and smart manufacturing within regulated industries. Policymakers increasingly recognize the need for advanced technologies to strengthen pharmaceutical supply chains, improve product quality, and accelerate clinical-research efficiency. By launching a global platform that directly addresses these policy aims, Teva contributes to industry-wide modernization efforts and helps establish standards for collaborative innovation, data-driven compliance, and responsible AI integration across the pharmaceutical lifecycle. The program’s focus on operational transparency and patient impact aligns with evolving regulatory guidance and global health-system expectations.
Teva’s launch of the Teva Rise innovation platform marks a pivotal moment for the pharmaceutical industry, accelerating the adoption of disruptive technologies that strengthen R&D, optimize manufacturing, modernize supply-chain operations, and enhance patient experience. By opening its global ecosystem to startups and technology innovators, Teva is building a future in which AI-powered development, smart factories, and digital-health integrated care models redefine how therapies are created and delivered. As the company advances its Pivot to Growth strategy, Teva Rise stands as a powerful example of how collaboration, technology, and scientific rigor can drive meaningful transformation for patients worldwide.
Source: Teva Pharmaceutical Industries Ltd. press release
